Trial Profile
A Pilot Study Utilizing Escitalopram to Address Cognitive Dysfunction in Glioma Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 04 Jan 2024 Planned End Date changed from 1 Dec 2024 to 1 Aug 2025.
- 04 Jan 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.
- 04 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.